16263-53-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3,5-Dichlorobenzo[d]isoxazole is used as a building block in the synthesis of pharmaceuticals and agrochemicals for its ability to enhance the properties of these compounds, such as potency, selectivity, and stability.
Used in Organic Chemistry:
DCBI is used as a reagent in chemical reactions to introduce the 3,5-dichlorobenzo[d]isoxazole structural motif into various organic molecules, thereby expanding the scope of chemical synthesis and the development of new compounds with desired properties.
Used in Research and Development:
3,5-Dichlorobenzo[d]isoxazole is employed in research and development for its potential pharmaceutical applications, as it has been studied for its potential to treat various diseases and conditions. This includes exploring its biological activity and evaluating its efficacy and safety in preclinical and clinical studies.

Upstream product

• 24603-63-2 5-chloro-3-hydroxy-1,2-benzoisoxazole 
• 24603-63-2 5-Chloro-benzo[d]isoxazol-3-one 
• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 
• 37551-43-2 N-(5-chlorosalicyl) hydroxamic acid 

Downstream Products

• 24603-63-2 5-chloro-3-hydroxy-1,2-benzoisoxazole 
• 16263-61-9 5-chloro-3-phenoxy-benzo[d]isoxazole 

Relevant academic research and scientific papers

Isoxazole derivatives

An isoxazole compound having the following formula: wherein R1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.

Synthesis and Biological Evaluation of 1-(1,2-Benzisothiazol-3-yl)- and (1,2-Benzisoxazol-3-yl)piperazine Derivatives as Potential Antipsychotic Agents

Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens.Structure-activity relationships within the series are discussed.Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests.It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h.The compound's lack of typical neuroleptic-like effects in therat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy.Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile.Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.